{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Discontinued during cycles 1 - 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Discontinued during cycles 7 - 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Treatment discontinuation for all reasons in cycles 1 - 6 and cycles 7 - 12","groups":[{"description":"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.\n\nParticipants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12.","id":"OG000","title":"Carfilzomib Plus Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled and treated participants","reportingStatus":"POSTED","timeFrame":"Cycles 1 - 6 and 7 - 12 (each cycle is 28 days)","title":"Number of Participants Who Discontinued Carfilzomib in Cycles 1 to 6 and 7 to 12","type":"SECONDARY","unitOfMeasure":"Participants"}